Product record
Buprenorphine Hci Naloxone Sublingula: batches declared Not of Standard Quality
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts, Jan 2019 to Sep 2026
1 batch of products named "Buprenorphine Hci Naloxone Sublingula" (as printed by the testing lab) failed a CDSCO or state drug-testing laboratory test in September 2026. This is a record of specific batches, it does not mean the molecule or every brand is unsafe.
Records by type
1 record linked to Buprenorphine Hci Naloxone Sublingula in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A failed batch is not a verdict on every pack of this product. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches
| Batch | Manufacturer | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Batch SLTE26026Mfg May 2026 · Exp Apr 2028 | Swift Life Sciences Pvt. LtdUttarakhand | The content of Buprenorphine found to be 0.451 mg per tablet (112.75%) against labelled claim of 0.4 mg per tabletLabelling | SDTL, PunjabState lab | Sep 2026 |
How to use this. Match the batch number on your strip or bottle against the list. If your batch is listed, return it to the pharmacy and ask for a replacement; if not, the product is not on any alert as of September 2026. Check any batch number.